© 1996 American Heart Association, Inc.
Articles |
Both Lipolysis and Hepatic Uptake of VLDL Are Impaired in Transgenic Mice Coexpressing Human Apolipoprotein E*3Leiden and Human Apolipoprotein C1
the TNO-Prevention and Health (M.C.J., V.E.H.D., L.M.H.), Gaubius Laboratory, Leiden; MGC-Department of Human Genetics (P.J.J. van G., A. van der Z., R.R.F., M.H.H.) and Medical Biochemistry (M.L.B.), Department of Molecular Carcinogenesis, Leiden University, Leiden; and the Department of Medicine (M.J.T.M.M.), Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, Netherlands.
Correspondence to Dr L.M. Havekes, TNO-PG, Gaubius Laboratory, PO Box 2215, 2301 CE Leiden, Netherlands. E-mail LM.HAVEKES@PG.TNO.NL.
Abstract
Transgenic mice overexpressing human APOE*3Leiden are highly susceptible to diet-induced hyperlipoproteinemia and atherosclerosis due to a defect in hepatic uptake of remnant lipoproteins. In addition to the human APOE*3Leiden gene, these mice carry the human APOC1 gene (APOE*3Leiden-C1). To investigate the possible effect of simultaneous expression of the human APOC1 gene, we examined the phenotypic expression in these APOE*3Leiden-C1 mice in relation to transgenic mice expressing the APOE*3Leiden gene without the APOC1 gene (APOE*3Leiden-HCR). APOE*3Leiden-C1 and APOE*3Leiden-HCR mice had comparable liver expression for the APOE*3Leiden transgene and high total cholesterol levels on a sucrose-based diet compared with control mice (4.3 and 4.3 versus 2.1 mmol/L). In addition, on this diet APOE*3Leiden-C1 mice displayed significantly higher serum triglyceride levels than APOE*3Leiden-HCR mice and control mice (4.4 versus 0.6 and 0.2 mmol/L). Elevated triglyceride and cholesterol levels were mainly in the VLDL-sized lipoproteins. In vivo turnover studies with endogenously triglyceride-labeled VLDL showed a reduced VLDL triglyceride fractional catabolic rate for APOE*3Leiden-C1 and APOE*3Leiden-HCR mice compared with control mice (3.5 and 11.0 versus 20.4 pools per hour). To study whether the difference in fractional catabolic rates between the two transgenic strains was due to an inhibiting effect of apoC1 on the extrahepatic lipolysis or hepatic-mediated uptake of VLDL, turnover experiments were performed in functionally hepatectomized mice. Strikingly, both APOE*3Leiden-C1 and APOE*3Leiden-HCR mice showed a decreased lipolytic rate of VLDL triglyceride in the extrahepatic circulation compared with control mice (1.5 and 1.8 versus 6.3 pools per hour). We conclude that next to an impaired hepatic uptake, overexpression of the APOE*3Leiden gene influences the extrahepatic lipolysis of VLDL triglycerides, whereas simultaneous overexpression of the APOC1 gene leads to a further decrease in hepatic clearance of VLDL.
Key Words: apolipoprotein C • apolipoprotein E • hyperlipoproteinemia • transgenic mice
This article has been cited by other articles:
 |
|
 |
|
  C. J. A. Moen, A. P. Tholens, P. J. Voshol, W. de Haan, L. M. Havekes, P. Gargalovic, A. J. Lusis, K. W. van Dyk, R. R. Frants, M. H. Hofker, et al. The Hyplip2 locus causes hypertriglyceridemia by decreased clearance of triglycerides J. Lipid Res., October 1, 2007; 48(10): 2182 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Duivenvoorden, P. J Voshol, P. C. Rensen, W. van Duyvenvoorde, J. A Romijn, J. J Emeis, L. M Havekes, and W. F Nieuwenhuizen Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice. Am. J. Clinical Nutrition, August 1, 2006; 84(2): 312 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Duivenvoorden, B. Teusink, P. C. N. Rensen, F. Kuipers, J. A. Romijn, L. M. Havekes, and P. J. Voshol Acute inhibition of hepatic {beta}-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity J. Lipid Res., May 1, 2005; 46(5): 988 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. P. Berbee, C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. N. Rensen Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL J. Lipid Res., February 1, 2005; 46(2): 297 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kolmakova, P. Kwiterovich, D. Virgil, P. Alaupovic, C. Knight-Gibson, S. F. Martin, and S. Chatterjee Apolipoprotein C-I Induces Apoptosis in Human Aortic Smooth Muscle Cells via Recruiting Neutral Sphingomyelinase Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 264 - 269. [Abstract] [Full Text]
|
|
|
|
|
|
K. Conde-Knape, A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase J. Lipid Res., December 1, 2002; 43(12): 2136 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Cohn, M. Tremblay, R. Batal, H. Jacques, L. Veilleux, C. Rodriguez, L. Bernier, O. Mamer, and J. Davignon Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects J. Lipid Res., October 1, 2002; 43(10): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Gautier, D. Masson, M. C. Jong, L. Duverneuil, N. Le Guern, V. Deckert, J.-P. P. de Barros, L. Dumont, A. Bataille, Z. Zak, et al. Apolipoprotein CI Deficiency Markedly Augments Plasma Lipoprotein Changes Mediated by Human Cholesteryl Ester Transfer Protein (CETP) in CETP Transgenic/ApoCI-knocked Out Mice J. Biol. Chem., August 23, 2002; 277(35): 31354 - 31363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Mensenkamp, B. Teusink, J. F.W. Baller, H. Wolters, R. Havinga, K. W. van Dijk, L. M. Havekes, and F. Kuipers Mice Expressing Only the Mutant APOE3Leiden Gene Show Impaired VLDL Secretion Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1366 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Post, B. de Roos, M. Vermeulen, L. Afman, M. C. Jong, V. E. H. Dahlmans, L. M. Havekes, F. Stellaard, M. B. Katan, and H. M. G. Princen Cafestol Increases Serum Cholesterol Levels in Apolipoprotein E*3-Leiden Transgenic Mice by Suppression of Bile Acid Synthesis Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1551 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Van Eck, N. Herijgers, K. W. Van Dijk, L. M. Havekes, M. H. Hofker, P. H. E. Groot, and T. J. C. Van Berkel Effect of Macrophage-Derived Mouse ApoE, Human ApoE3-Leiden, and Human ApoE2 (Arg158->Cys) on Cholesterol Levels and Atherosclerosis in ApoE-Deficient Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Jong, W. L. Hendriks, L. C. van Vark, V. E. H. Dahlmans, J. E. M. Groener, and L. M. Havekes Oxidized VLDL Induces Less Triglyceride Accumulation in J774 Macrophages Than Native VLDL Due to an Impaired Extracellular Lipolysis Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 144 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R Mensenkamp, M. C Jong, H. van Goor, M. J. A. van Luyn, V. Bloks, R. Havinga, P. J. Voshol, M. H. Hofker, K. W. van Dijk, L. M. Havekes, et al. Apolipoprotein E Participates in the Regulation of Very Low Density Lipoprotein-Triglyceride Secretion by the Liver J. Biol. Chem., December 10, 1999; 274(50): 35711 - 35718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. van Dijk, B. J.M. van Vlijmen, M. P.J. de Winther, B. van ’t Hof, A. van der Zee, H. van der Boom, L. M. Havekes, and M. H. Hofker Hyperlipidemia of ApoE2(Arg158-Cys) and ApoE3-Leiden Transgenic Mice Is Modulated Predominantly by LDL Receptor Expression Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2945 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, Z.-S. Ji, W. J. Brecht, S. C. Rall Jr, J. M. Taylor, and R. W. Mahley Overexpression of Apolipoprotein E3 in Transgenic Rabbits Causes Combined Hyperlipidemia by Stimulating Hepatic VLDL Production and Impairing VLDL Lipolysis Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2952 - 2959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Jong, M. H. Hofker, and L. M. Havekes Role of ApoCs in Lipoprotein Metabolism : Functional Differences Between ApoC1, ApoC2, and ApoC3 Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 472 - 484. [Full Text] [PDF]
|
|
|
|
|
|
F. de Beer, W. L. Hendriks, L. C. van Vark, S. W.A. Kamerling, K. W. van Dijk, M. H. Hofker, A. H.M. Smelt, and L. M. Havekes Binding of ß-VLDL to Heparan Sulfate Proteoglycans Requires Lipoprotein Lipase, Whereas ApoE Only Modulates Binding Affinity Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 633 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. van Dijk, B. J. M. van Vlijmen, H. B. van't Hof, A. van der Zee, S. Santamarina-Fojo, T. J.C. van Berkel, L. M. Havekes, and M. H. Hofker In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE J. Lipid Res., February 1, 1999; 40(2): 336 - 344. [Abstract] [Full Text]
|
|
|
|
|
|
B. J.M. van Vlijmen, K. W. van Dijk, H. B. van't Hof, P. J.J. van Gorp, A. van der Zee, H. van der Boom, M. L. Breuer, M. H. Hofker, and L. M. Havekes In the Absence of Endogenous Mouse Apolipoprotein E, Apolipoprotein E*2(Arg-158 right-arrow Cys) Transgenic Mice Develop More Severe Hyperlipoproteinemia than Apolipoprotein E*3-Leiden Transgenic Mice J. Biol. Chem., November 29, 1996; 271(48): 30595 - 30602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Swift, M. H. Farkas, A. S. Major, K. Valyi-Nagy, M. F. Linton, and S. Fazio A Recycling Pathway for Resecretion of Internalized Apolipoprotein E in Liver Cells J. Biol. Chem., June 15, 2001; 276(25): 22965 - 22970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Teusink, A. R. Mensenkamp, H. van der Boom, F. Kuipers, K. W. van Dijk, and L. M. Havekes Stimulation of the in Vivo Production of Very Low Density Lipoproteins by Apolipoprotein E Is Independent of the Presence of the Low Density Lipoprotein Receptor J. Biol. Chem., October 26, 2001; 276(44): 40693 - 40697. [Abstract] [Full Text] [PDF]
|
|